The Effect of Adding Pancreatin to Standard Otilinium Bromide and Simethicone Treatment in Type 2 Diabetes Mellitus Patients with Irritable Bowel Syndrome

Overview

Journal Sci Rep

Specialty Science

Date 2024 Oct 21

PMID 39433866

Authors

Hulusi Can Karpuzcu

Beril Turan Erdogan

Cagdas Erdogan

Affiliations

Soon will be listed here.

Abstract

This study aimed to assess the impact of adding pancreatin (a pancreatic enzyme derivative) to standard treatment on patients diagnosed with Irritable Bowel Syndrome (IBS) and Type 2 Diabetes Mellitus (T2DM). IBS and T2DM frequently coexist, leading to significant gastrointestinal symptoms and a decrease in quality of life. Gastrointestinal symptoms arising in T2DM patients present challenges in management for both clinicians and patients. Standard treatments may not fully address these symptoms. Recent studies suggest that pancreatic enzyme replacement therapy may offer additional benefits. This study investigates whether adding pancreatin to standard treatment can improve gastrointestinal outcomes in this patient population. Conducted as a prospective observational study, the research involved patients diagnosed with IBS according to Rome IV criteria and having concomitant T2DM. The patients were divided into two groups: one receiving standard dual treatment (otilinium bromide + simethicone) and the other receiving a triple therapy including a pancreatin derivative in addition to the standard treatment. Various clinical scores and measurements, including Visual Analog Scale (VAS), Bristol Stool Chart (BSC), Irritable Bowel Syndrome-Severity Scoring System (IBS-SSS), and Irritable Bowel Syndrome Quality of Life Instrument (IBS-QOL), were assessed before and after treatment. The study comprised 121 patients, with a median age of 41 years (interquartile range [IQR] 38-48), of whom approximately 70.2% were female. Fifty-eight patients (47.9%) received dual therapy, while sixty-three patients (52.1%) received triple therapy. Before treatment, both groups exhibited similar pre-treatment Bristol stool scale results: normal (39.7% and 49.2%) and constipation (37.9% and 31.7%) in the dual and triple therapy subgroups, respectively (p > 0.05). Post-treatment, the triple therapy group showed a significantly higher proportion of normal cases on the Bristol stool scale (82.5%) compared to the dual therapy group (44.8%) (p < 0.001). After treatment, the triple therapy group demonstrated statistically significant improvements in VAS score (p < 0.001), IBS-SSS (p < 0.001), and IBS-QOL (p < 0.001) compared to the dual therapy group. There were no significant differences between groups in BMI, HbA1c levels, duration of diabetes, or diabetes treatment at baseline (p > 0.05 for all parameters). The findings suggest that adding pancreatin to standard therapies significantly enhanced the quality of life for patients with both IBS and T2DM, demonstrating improvements across various symptom measurements and indicating the potential benefits of this supplementary therapy in managing gastrointestinal symptoms in this population. Further studies are warranted to explore its broader clinical implications and mechanisms of action.

References

Hungin A, Whorwell P, Tack J, Mearin F . The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003; 17(5):643-50. DOI: 10.1046/j.1365-2036.2003.01456.x. View

Krishnan B, Babu S, Walker J, Walker A, Pappachan J . Gastrointestinal complications of diabetes mellitus. World J Diabetes. 2013; 4(3):51-63. PMC: 3680624. DOI: 10.4239/wjd.v4.i3.51. View

Du Y, Rayner C, Jones K, Talley N, Horowitz M . Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management. Diabetes Care. 2018; 41(3):627-637. DOI: 10.2337/dc17-1536. View

Piciucchi M, Capurso G, Archibugi L, Delle Fave M, Capasso M, Delle Fave G . Exocrine pancreatic insufficiency in diabetic patients: prevalence, mechanisms, and treatment. Int J Endocrinol. 2015; 2015:595649. PMC: 4393909. DOI: 10.1155/2015/595649. View

Leeds J, Hopper A, Sidhu R, Simmonette A, Azadbakht N, Hoggard N . Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol. 2009; 8(5):433-8. DOI: 10.1016/j.cgh.2009.09.032. View

Akyuz F, Celebi A, Dogan I, Erzin Y, Kav T, Soyturk M . Functional Bowel Disorder Management in Routine Practice with Tips for Hot Topics: Expert Opinion Review. Turk J Gastroenterol. 2024; 35(6):423-439. PMC: 11232060. DOI: 10.5152/tjg.2024.24029. View

Boeckxstaens G, Corazziari E, Mearin F, Tack J . IBS and the role of otilonium bromide. Int J Colorectal Dis. 2012; 28(3):295-304. DOI: 10.1007/s00384-012-1598-0. View

Martinez-Vazquez M, Vazquez-Elizondo G, Gonzalez-Gonzalez J, Gutierrez-Udave R, Maldonado-Garza H, Bosques-Padilla F . Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012; 77(2):82-90. DOI: 10.1016/j.rgmx.2012.04.002. View

de la Iglesia-Garcia D, Huang W, Szatmary P, Baston-Rey I, Gonzalez-Lopez J, Prada-Ramallal G . Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis. Gut. 2016; 66(8):1354-1355. PMC: 5530474. DOI: 10.1136/gutjnl-2016-312529. View

10.

Futagami S, Kessoku T, Kasai Y, Higurashi T, Nakajima A, Agawa S . Comparison of pancreatic enzyme abnormalities and protease-activated receptor-2-positive eosinophils in the duodenum of patients with functional dyspepsia-irritable bowel syndrome overlap with functional dyspepsia alone in Asian populations. J Gastroenterol Hepatol. 2023; 38(10):1778-1786. DOI: 10.1111/jgh.16250. View

11.

Whitcomb D, Bodhani A, Beckmann K, Sander-Struckmeier S, Liu S, Fuldeore M . Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus. Pancreas. 2015; 45(5):679-86. DOI: 10.1097/MPA.0000000000000514. View

12.

Zsori G, Illes D, Terzin V, Ivany E, Czako L . Exocrine pancreatic insufficiency in type 1 and type 2 diabetes mellitus: do we need to treat it? A systematic review. Pancreatology. 2018; 18(5):559-565. DOI: 10.1016/j.pan.2018.05.006. View

13.

Emmanuel A, Landis D, Peucker M, Hungin A . Faecal biomarker patterns in patients with symptoms of irritable bowel syndrome. Frontline Gastroenterol. 2016; 7(4):275-282. PMC: 5036220. DOI: 10.1136/flgastro-2015-100651. View

14.

Talley N, Holtmann G, Nguyen Q, Gibson P, Bampton P, Veysey M . Undiagnosed pancreatic exocrine insufficiency and chronic pancreatitis in functional GI disorder patients with diarrhea or abdominal pain. J Gastroenterol Hepatol. 2017; 32(11):1813-1817. DOI: 10.1111/jgh.13791. View

15.

Singh V, Haupt M, Geller D, Hall J, Diez P . Less common etiologies of exocrine pancreatic insufficiency. World J Gastroenterol. 2017; 23(39):7059-7076. PMC: 5656454. DOI: 10.3748/wjg.v23.i39.7059. View

16.

Tahtaci M, Algin O, Karakan T, Yurekli O, Alisik M, Koseoglu H . Can pancreatic steatosis affect exocrine functions of pancreas?. Turk J Gastroenterol. 2018; 29(5):588-594. PMC: 6284608. DOI: 10.5152/tjg.2018.17696. View

17.

Money M, Walkowiak J, Virgilio C, Talley N . Pilot study: a randomised, double blind, placebo controlled trial of pancrealipase for the treatment of postprandial irritable bowel syndrome-diarrhoea. Frontline Gastroenterol. 2011; 2(1):48-56. PMC: 3009417. DOI: 10.1136/fg.2010.002253. View

18.

Suarez F, Levitt M, Adshead J, Barkin J . Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. Dig Dis Sci. 1999; 44(7):1317-21. DOI: 10.1023/a:1026675012864. View

19.

Olmos J, Piskorz M, Litwin N, Schaab S, Tevez A, Bravo-Velez G . Exocrine Pancreatic Insufficiency is Undiagnosed in Some Patients with Diarrhea-Predominant Irritable Bowel Syndrome Using the Rome IV Criteria. Dig Dis Sci. 2022; 67(12):5666-5675. DOI: 10.1007/s10620-022-07568-8. View

20.

Graham D, Ketwaroo G, Money M, Opekun A . Enzyme therapy for functional bowel disease-like post-prandial distress. J Dig Dis. 2018; 19(11):650-656. PMC: 6910206. DOI: 10.1111/1751-2980.12655. View